公开(公告)号：US20190016735A1

公开(公告)日：2019-01-17

申请号：US16067619

申请日：2017-01-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Leon M. Smith II ,  Vladimir Ladziata ,  Indawati De Lucca ,  Donald J.P. Pinto ,  Michael J. Orwat ,  Andrew K. Dilger ,  Kumar Balashanmuga Pabbisetty ,  Wu Yang ,  Scott A. Shaw ,  Peter W. Glunz ,  Manoranjan Panda

IPC: C07D513/04 ,  A61P9/10 ,  A61P15/10

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

公开(公告)号：US12286424B2

公开(公告)日：2025-04-29

申请号：US17998261

申请日：2021-05-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prasada Rao Jalagam ,  Susheel Jethanand Nara ,  Manoranjan Panda ,  Murugesan Natesan ,  Pratik Devasthale

IPC: C07H19/12 ,  C07D405/04 ,  C07D405/14 ,  C07D487/08

Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))

公开(公告)号：US11639353B2

公开(公告)日：2023-05-02

申请号：US17212210

申请日：2021-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61K31/4375 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20230124468A1

公开(公告)日：2023-04-20

申请号：US17960199

申请日：2022-10-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20210246136A1

公开(公告)日：2021-08-12

申请号：US17212210

申请日：2021-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US10723723B2

公开(公告)日：2020-07-28

申请号：US16344823

申请日：2017-11-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prashantha Gunaga ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Manoranjan Panda ,  Navnath Dnyanoba Yadav ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61P13/02 ,  A61P9/00 ,  A61P9/12 ,  A61P9/04 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20200131200A1

公开(公告)日：2020-04-30

申请号：US16739363

申请日：2020-01-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Leon M. Smith, II ,  Vladimir Ladziata ,  Indawati De Lucca ,  Donald J.P. Pinto ,  Michael J. Orwat ,  Andrew K. Dilger ,  Kumar Balashnmuga Pabbisetty ,  Wu Yang ,  Scott A. Shaw ,  Peter W. Glunz ,  Manoranjan Panda

IPC: C07D513/04 ,  A61P9/10 ,  A61P15/10 ,  C07D213/64 ,  C07D231/12 ,  C07D401/14 ,  C07D231/54 ,  C07D401/12 ,  C07D413/12 ,  C07D471/12 ,  C07D471/04 ,  C07D231/18

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.